Nurix Therapeutics Reports 36% Revenue Decline and $89.5 Million Net Loss in Latest Quarter

Nurix Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending May 31, 2026. The company recorded total revenue of $9.0 million for the three months ended May 31, 2026, a decrease of 36% from $14.1 million in the same period last year. For the six months, revenue fell to $15.3 million from $62.5 million, primarily due to the absence of license revenue, which had contributed $30 million in the previous year. The decline in collaboration revenue was attributed to the conclusion of the initial research term for certain drug targets under agreements with partners such as Gilead and Sanofi.

Operating expenses increased to $103.2 million for the three months ended May 31, 2026, compared to $92.4 million in the prior year, driven by higher research and development costs, which rose to $87.7 million from $78.1 million. The net loss for the quarter was $89.5 million, significantly higher than the $43.5 million loss reported in the same quarter of 2025. For the six-month period, the net loss reached $176.7 million, up from $99.8 million in the previous year, reflecting increased spending on clinical trials and operational costs.

In terms of strategic developments, Nurix announced a global collaboration agreement with Roche on June 6, 2026, which is expected to provide an upfront payment of $700 million and potential total payments of up to $2.3 billion. This agreement is anticipated to enhance the company's financial position and support ongoing clinical trials for its lead drug candidate, bexobrutideg (NX-5948). The company also continues to engage in collaborations with Gilead, Sanofi, and Pfizer, which have collectively provided $489 million in non-dilutive financing to date.

As of May 31, 2026, Nurix reported cash, cash equivalents, and marketable securities totaling $443.5 million, a decrease from $606.8 million at the end of the previous fiscal year. The company expects its current financial resources, along with the anticipated Roche payment, to sustain operations for at least the next 12 months. However, management indicated that substantial additional funding will be necessary to support ongoing clinical development and commercialization efforts. The company remains focused on advancing its drug candidates through clinical trials while navigating the complexities of the biopharmaceutical landscape.